SavedAdd your journal

Journals / Retina-Vitreus / 2022 / Cilt: 31 - Sayı: 1

Factors Affecting the Visual Acuity and Anatomic Recovery in the Treatment of Diabetic Macular Edema

Naciye Kabataş
Osman Çelikay
Pages
50–55
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the multivariate regression analysis, it is found that the poor visual acuity is highly correlated with severe non-proliferative diabetic retinopathy and proliferative diabetic retinopathy, while shows an interrelation with the presence of subretinal fluid in OCT, exudate in fovea, and ellipsoid zone damage (p=0.004, p=0.009, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the parameters which affect the anatomic and functional results of diabetic macular edema (DME) patients who are treated with intravitreal ranibizumab.
📊
Key Findings & Data:Results: 110 eyes of 65 patients are included in this research.
💡
Conclusion & Impact:In the multivariate regression analysis, it is found that the poor visual acuity is highly correlated with severe non-proliferative diabetic retinopathy and proliferative diabetic retinopathy, while shows an interrelation with the presence of subretinal fluid in OCT, exudate in fovea, and ellipsoid zone damage (p=0.004, p=0.009, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the parameters which affect the anatomic and functional results of diabetic macular edema (DME) patients who are treated with intravitreal ranibizumab. Methods: Patients who have been diagnosed with DME are included in this research. Patients who have been treated with Pro Re Nata (PRN) regime before three months of ranibizumab injection are included in this research. Stage of diabetic retinopathy, type of edema in OCT, epiretinal membrane (ERM) ellipsoid zone damage, and presence of exudate in subretinal fluid and fovea of the patients are determined. The effect of these parameters on final central fovea thickness and best-corrected visual acuity is investigated. Results: 110 eyes of 65 patients are included in this research. In the multivariate regression analysis, it is found that the poor visual acuity is highly correlated with severe non-proliferative diabetic retinopathy and proliferative diabetic retinopathy, while shows an interrelation with the presence of subretinal fluid in OCT, exudate in fovea, and ellipsoid zone damage (p=0.004, p=0.009, p

🔖

Cite This Article

Kabataş, N., Çelikay, O. (2022). Factors Affecting the Visual Acuity and Anatomic Recovery in the Treatment of Diabetic Macular Edema. Retina-Vitreus, Cilt: 31 - Sayı: 1, 50–55. https://ajindex.com/articles/589025

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. . Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984
  2. Campos A, Campos EJ, Martins J, et al. Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema. Acta Ophthalmol. 2017
  3. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985
  4. Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopaty and tumors. J Bio Chem. 1999
  5. 23463-67. 5. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12- month data
  6. report 2. Ophthalmology. 2010
  7. 1086 e2. 6. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study
  8. phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011
  9. Garweg JG.A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE).Klin Monbl Augenheilkd. 2020
  10. Ashraf M, Souka A, Adelman R. Predicting outcomes to anti- vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema
  11. a review of the literature. Br J Ophthalmol. 2016
  12. Lai IA, Hsu WC, Yang CM, et al. Prognostic factors of short term outcomes of intravitreal ranibizumab in diabetic macular edema. Int J Ophthalmol. 2017
  13. Sophie R, Lu N, Campochiaro PA. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology 2015
  14. Bressler SB1, Qin H, Beck RW, et al. 3rd
  15. Diabetic Retinopathy Clinical Research Network. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012
  16. Kaya M, Karahan E, Ozturk T, Kocak N, Kaynak. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal